Equities Analysts Issue Forecasts for Annovis Bio, Inc.’s Q1 2025 Earnings (NYSE:ANVS)

Annovis Bio, Inc. (NYSE:ANVSFree Report) – Investment analysts at HC Wainwright issued their Q1 2025 earnings estimates for shares of Annovis Bio in a note issued to investors on Tuesday, April 2nd. HC Wainwright analyst R. Selvaraju forecasts that the company will post earnings per share of ($0.48) for the quarter. HC Wainwright currently has a “Buy” rating and a $30.00 target price on the stock. The consensus estimate for Annovis Bio’s current full-year earnings is ($5.07) per share. HC Wainwright also issued estimates for Annovis Bio’s Q2 2025 earnings at ($0.69) EPS, Q3 2025 earnings at ($0.77) EPS, Q4 2025 earnings at ($0.84) EPS and FY2025 earnings at ($2.82) EPS.

Several other analysts have also recently commented on the stock. Brookline Capital Management cut shares of Annovis Bio from a “buy” rating to a “hold” rating and set a $9.00 target price for the company. in a research note on Wednesday, February 28th. Canaccord Genuity Group started coverage on shares of Annovis Bio in a research note on Friday, December 29th. They issued a “buy” rating and a $36.00 target price for the company. Finally, Canaccord Genuity Group started coverage on shares of Annovis Bio in a report on Friday, December 29th. They issued a “buy” rating and a $36.00 price target for the company.

Check Out Our Latest Analysis on ANVS

Annovis Bio Stock Performance

ANVS stock opened at $11.14 on Wednesday. Annovis Bio has a one year low of $5.42 and a one year high of $22.49. The stock has a market capitalization of $117.86 million, a PE ratio of -2.61 and a beta of 1.59. The company has a fifty day moving average of $10.17 and a 200-day moving average of $10.01.

Hedge Funds Weigh In On Annovis Bio

Large investors have recently made changes to their positions in the stock. Tower Research Capital LLC TRC increased its holdings in shares of Annovis Bio by 67.9% in the 1st quarter. Tower Research Capital LLC TRC now owns 2,561 shares of the company’s stock valued at $39,000 after purchasing an additional 1,036 shares in the last quarter. Private Trust Co. NA purchased a new position in Annovis Bio during the 4th quarter valued at about $56,000. Northern Trust Corp purchased a new position in Annovis Bio during the 2nd quarter valued at about $145,000. Greenwich Wealth Management LLC purchased a new position in Annovis Bio during the 4th quarter valued at about $192,000. Finally, Wealthspire Advisors LLC increased its holdings in Annovis Bio by 9.9% during the 4th quarter. Wealthspire Advisors LLC now owns 10,990 shares of the company’s stock valued at $206,000 after acquiring an additional 990 shares in the last quarter. Hedge funds and other institutional investors own 15.83% of the company’s stock.

Annovis Bio Company Profile

(Get Free Report)

Annovis Bio, Inc, a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which is in Phase 3 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases.

Featured Stories

Earnings History and Estimates for Annovis Bio (NYSE:ANVS)

Receive News & Ratings for Annovis Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Annovis Bio and related companies with MarketBeat.com's FREE daily email newsletter.